| Market Capitalization (Millions $) |
1,499 |
| Shares
Outstanding (Millions) |
178 |
| Employees |
65 |
| Revenues (TTM) (Millions $) |
315 |
| Net Income (TTM) (Millions $) |
13 |
| Cash Flow (TTM) (Millions $) |
53 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Xeris Biopharma Holdings Inc. is a US-based pharmaceutical company focused on developing and commercializing innovative, differentiated therapeutics for people with serious and life-threatening conditions. Xeris was founded in 2005 and is headquartered in Chicago, Illinois.
The company's primary focus is on the development of injectable and infusible drug formulations that are stable at room temperature, making them more convenient and accessible for patients. Their lead product, Gvoke HypoPen, is a ready-to-use, premixed, pre-measured glucagon emergency kit that treats severe hypoglycemia in adults and children with diabetes. The kit received FDA approval in August 2019 and is available for purchase in the US.
Xeris has also developed several other products under development, including a ready-to-use glucagon rescue pen for hypoglycemia associated with insulin therapy, a stable liquid glucagon for use in a healthcare setting, and an epilepsy treatment using Xeris' proprietary formulation technology.
In addition to its internal development programs, Xeris has entered into strategic partnerships and collaborations to further advance their technology and product pipeline. These partnerships include collaborations with Zealand Pharma, Intarcia Therapeutics, and Vizient, among others.
Xeris is led by a highly experienced executive team and has raised over $100 million in funding, including a successful initial public offering in 2018. The company has also been recognized for its innovation and leadership in the industry, receiving awards such as the Red Herring Top 100 North America and being named as one of FierceBiotech's Fierce 15 in 2018.
Overall, Xeris Biopharma Holdings Inc. is a rapidly growing and innovative pharmaceutical company with a strong focus on developing therapeutics that improve patient outcomes and make treatments more accessible and convenient for patients.
Company Address: 1375 West Fulton Street Chicago 60607 IL
Company Phone Number: 445-5704 Stock Exchange / Ticker: NASDAQ XERS
|
16% 
99.19 %